How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

778 results for

Insight and Judgement

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Position Paper for the Treatment of Nightmare Disorder in Adults

evidence and clinical judgement of the task force. Positions of “may be used” indicate that the evidence or expert consensus is less clear, either in favor or against the use of a treatment option. The interventions listed below are in alphabetical order within the position statements rather than clinical preference: this is not meant to be instructive of the order in which interventions should be used. Position Statements: The following therapy is recommended for the treatment of PTSD-associated (...) judgement of the task force regarding the treatment of PTSD-associated nightmares and nightmares without a clear etiology (ie, nightmare disorder). POSITION STATEMENTS The AASM supports the following positions on the treatment of nightmare disorder in adults. Note that the interventions are listed in alphabetical order within the position statements. The order in which they are listed is not meant to be instructive of the order in which interventions should be used. Behavioral and Psychological

2018 American Academy of Sleep Medicine

182. Neonatal jaundice

a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect. The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate. This guideline does not address all elements of standard practice and accepts that individual (...) of metabolism if baby looks unwell and the jaundice is severe, e.g. galactosaemia, tyrosinaemia · Liver disease 4,23 : o Albumin § Decreased levels result in poor bilirubin binding capacity and risk of bilirubin toxicity o Liver function tests (LFT) as liver enzymes may be increased, e.g. in congenital infections, inborn errors of metabolism Refer to online version, destroy printed copies after use Page 15 of 40 Queensland Clinical Guideline: Neonatal jaundice 5.3 Prolonged jaundice Clinical judgement

2018 Queensland Health

183. Selexipag (Uptravi) - For the long-term treatment of pulmonary arterial hypertension (PAH)

. 5. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(26):2522-33. 6. European Medicines Agency. European Public Assessment Report, selexipag (Uptravi®) 1 April 2016 EMA/CH/C/003774/0000. 7. Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from (...) at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

2018 Scottish Medicines Consortium

184. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value

as more than $10,000 in healthcare company stock or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers ©Institute for Clinical and Economic Review, 2018 Page v Evidence Report – CAR-T Therapies for B-Cell Cancers Return to Table of Contents Table of Contents Executive Summary ES1 1. Introduction 1 1.1 Background 1 1.2 Scope of the Assessment 4 1.3 Definitions 7 1.4 Insights Gained from Discussions with Patients and Patient Groups 10 1.5 (...) the preparation and administration of the CAR-T therapy as well as management of side effects. Novartis has entered into an outcomes-based pricing arrangement with the Centers for Medicare and Medicaid Services (CMS) in which it appears that payment will be provided only for pediatric and young adult patients who respond to treatment with tisagenlecleucel at the end of the first month post-infusion. 10 Insights Gained from Discussions with Patients and Patient Groups Several themes emerged from our discussion

2018 California Technology Assessment Forum

187. Building Evaluation Capacity

). The internal scan was used to understand the level of evaluation capacity and identify evaluation resource and support needs. The external scan provided insight into the function and form that support high evaluation capacity within public health organizations. Program evaluation is routine practice at the ROP–PH. Between 2011 and 2016, staff completed 75 program evaluations. (3) Despite this active involvement, evaluation capacity could be strengthened. Staff primarily conduct process evaluations (...) ; and 10 ? the reputability of the publication source: peer-reviewed, evaluation journal. The appraisal excluded three papers. It was not appropriate to critically appraise the methodology of the papers. No prescribed method exists for developing conceptual models; they often evolve over time from the insights of researchers. (5) Each ECB conceptual model was individually analyzed and critiqued using an adaptation of Fawcett’s Framework for Analyzing and Evaluating Conceptual Models in Nursing (see

2018 Peel Health Library

188. What is the evidence on the policy specifications, development processes and effectiveness of existing front-of-pack food labelling policies in the WHO European Region?

and Nutrition Action Plan 2015–2020 identified the introduction of interpretative, consumer-friendly FOPL as a priority policy issue. Based on surveys undertaken by the WHO Regional Office for Europe, most European countries have some form of FOPL, although fewer countries have interpretive systems that provide judgements about the relative healthfulness of foods. The synthesis question This report has synthesized information on the development and implementation of interpretive FOPL policies across the WHO (...) consumers to choose nutritionally favourable products. Policy considerations Based on the evidence synthesized in this report, a number of considerations can be identified for the adoption or review of FOPL policies at the national or regional level: • establish a consistent FOPL system to aid consumer use and understanding of the label; • utilize a system of interpretive FOPL that can provide evaluative judgements about product unhealthfulness, which appears to be a more effective way to support

2018 WHO Health Evidence Network

190. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine

and supporting documents are available at: http://sydney.edu.au/medicine/cdpc/resources/deprescribing-guidelines.php Disclaimer This document is a general guide to be followed subject to the clinician’s judgement and the person’s preference in each individual case. The guideline is designed to provide information to assist decision making and is based on the best evidence available at the time of developing this publication. Publication approval The guideline recommendations on pages 7-9 of this document (...) ) and a reasonable judgement of the limited potential for harm in a carefully monitored trial of discontinuation. This document is a general guide. Implementation of recommendations should only be conducted by qualified/trained personnel in consultation with appropriate parties (such as the prescriber, family, nurses and care staff). The people involved in these parties for consultation will vary by setting and should be considered in the local context, considering the scopes of practice of healthcare

2018 Clinical Practice Guidelines Portal

191. Roads to recovery: organisation and quality of stroke services

. They also found that in Manchester only two thirds of patients who were eligible for hyperacute care were admitted to these centres (Ramsay 2015). Qualitative research has provided insights on context and how changes were implemented (Fulop 2016). This underlined the benefits of a model in London which was more radical and simpler, with all potential stroke patients admitted to hyperacute units. By contrast, the model in Manchester was more complex and selective. Changes in London were launched (...) of these complex organisational questions cannot be answered by clinical trials. Some useful insights can be drawn from the rich and comprehensive national stroke audit data. This can help us to identify variation and trends in processes of care and potential relationships between organisational factors, care received and patient outcomes. Such research from observational studies cannot provide definitive answers. But careful analysis can identify emerging associations for discussion by decision-makers

2017 Publication 4887694

193. Homelessness at Transition

among young people leaving juvenile justice 50 Effectiveness of interventions to prevent homelessness and sustain housing among young people leaving juvenile justice 50 Other potential models 53 People leaving prison 56 Risk factors for homelessness among people leaving prison 57 Effectiveness of interventions to prevent homelessness and sustain housing among people leaving prison 61 Australian program evaluations 64 Additional insights into pre-prison release planning 65 People leaving hospital 69 (...) : inadequate housing for needs or delays in transfer to more suitable housing; safety concerns within the household or neighbourhood; and financial difficulties in part due to tenancies being established with debt. • Chronic homelessness may influence tenancy sustainment via social isolation. • Substance use and other mental health problems, including hoarding and squalor, were mentioned in a few studies but the evidence regarding these factors is equivocal. • Few insights were available about risk factors

2017 Sax Institute Evidence Check

195. Mobile Health Applications for Self-Management of Diabetes

objective description of the state of the science, a potential framework for assessing the applications and implications of the intervention, a summary of ongoing research, and information on future research needs. In particular, through the Technical Brief, AHRQ hopes to gain insight on the appropriate conceptual framework and critical issues that will inform future research. AHRQ expects that the evidence reports and technology assessments will inform individual health plans, providers, and purchasers (...) of each app when available, and whether each app has been shown to have a statistically significant effect on any diabetes-related outcomes. The first figure illustrates the risk of bias and overall quality judgements for individual studies, while the second figure shows the frequency of each risk of bias category among all the included studies (under the “Risk of Bias/Quality Assessment” section in “Findings”). In the figures, red represents high risk of bias, yellow means the risk is unclear

2018 Effective Health Care Program (AHRQ)

196. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review

review is intended to address some of the needs described in the NPS 2 and IOM 1 reports and others for evidence to inform guidelines and health care policy (including reimbursement policy) related to use of noninvasive nonpharmacological treatments as possible alternatives to opioids and other pharmacological treatments. This review also aims to provide additional insights into research gaps related to use of noninvasive nonpharmacological alternatives for treating five of the most common chronic

2018 Effective Health Care Program (AHRQ)

198. BSG and UKPBC primary biliary cholangitis treatment and management guidelines

is thought to be part of the underlying disease process in PBC. Clinical judgement should be used as to whether the rare concern about the possibility of haematological or other forms of malignant disease is sufficient to warrant biopsy exclusion on a case-by-case basis. In end-stage PBC, imaging to screen for the complications of cirrhosis should be routine as for cirrhosis of other aetiology. Histological features of pBC Histopathological evaluation of liver biopsy tissue in PBC can be challenging

2018 British Society of Gastroenterology

199. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value

, defined as more than $10,000 in healthcare company stock or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers ©Institute for Clinical and Economic Review, 2018 Page v Final Evidence Report – CAR-T Therapies for B-Cell Cancers Return to Table of Contents Table of Contents Executive Summary ES1 1. Introduction 1 1.1 Background 1 1.2 Scope of the Assessment 4 1.3 Definitions 7 1.4 Insights Gained from Discussions with Patients and Patient (...) month post- infusion. 10,16 Insights Gained from Discussions with Patients and Patient Groups Several themes emerged from our discussion with patients and patient groups. One was hope – CAR-T therapy represented hope for a cure in patients who had run out of treatment options. They were encouraged by the high initial response rates seen in the clinical trials. In addition, they hoped that CAR-T therapy would be less toxic than chemoradiation and stem cell transplant (SCT): no hair loss, mucositis

2018 California Technology Assessment Forum

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>